Diplomat sets the stage for IPO, acquires MedPro Rx

Print Friendly, PDF & Email

FLINT, Mich. — Diplomat Specialty Pharmacy last month filed for a $100 million initial public offering and acquired MedPro Rx Inc., which is focused on specialty infusion therapies, including immune globulin.

Diplomat, which had sales of $1.6 billion in the year ended March 31, filed with the Securities and Exchange Commission in early July to raise up to $100 million in the IPO.

The company bought Raleigh, N.C.-based MedPro Rx to expand its specialty infusion business and boost its presence in the mid-Atlantic states and the South.

“MedPro Rx shares our focus on caring for patients through personalized, high-touch service and communication,” said Diplomat chief executive officer Phil Hagerman.

Ron McFarlane, chief operating officer of MedPro Rx, said: “Diplomat’s focus on providing consistent, high-touch patient care matches our own approach for MedPro Rx patients. We are pleased to know that the care of our patients will continue to meet the quality standards our patients know and rely on.”

MedPro Rx places a strong emphasis on patient advocacy and providing resources for patients to live at their best.

“At MedPro Rx, we pride ourselves on setting the standard for specialty infusion care, incorporating personal interaction with the latest technology to provide a responsive, hassle-free experience for our patients,” added McFarlane. “Diplomat shares that vision and puts it into practice in each interaction with its own patients.”

The purchase follows Diplomat’s acquisition of American Homecare Federation Inc., an Enfield, Conn.-based provider of hemophilia pharmacy services.



Comments are closed.